MCID: PTH003
MIFTS: 34

Pathologic Nystagmus

Categories: Eye diseases, Neuronal diseases

Aliases & Classifications for Pathologic Nystagmus

MalaCards integrated aliases for Pathologic Nystagmus:

Name: Pathologic Nystagmus 12 15
Nystagmus 73

Classifications:



External Ids:

Disease Ontology 12 DOID:9650
ICD10 33 H55.0 H55.00
ICD9CM 35 379.50
MeSH 44 D009759
NCIt 50 C3282
UMLS 73 C0028738

Summaries for Pathologic Nystagmus

MalaCards based summary : Pathologic Nystagmus, also known as nystagmus, is related to congenital nystagmus and x-linked infantile nystagmus, and has symptoms including ophthalmoplegia, deficiencies of smooth pursuit movements and neurologic symptoms. An important gene associated with Pathologic Nystagmus is FRMD7 (FERM Domain Containing 7). The drugs Gabapentin and gamma-Aminobutyric acid have been mentioned in the context of this disorder. Affiliated tissues include eye, testes and brain, and related phenotypes are nervous system and vision/eye

Related Diseases for Pathologic Nystagmus

Graphical network of the top 20 diseases related to Pathologic Nystagmus:



Diseases related to Pathologic Nystagmus

Symptoms & Phenotypes for Pathologic Nystagmus

UMLS symptoms related to Pathologic Nystagmus:


ophthalmoplegia, deficiencies of smooth pursuit movements, neurologic symptoms

MGI Mouse Phenotypes related to Pathologic Nystagmus:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.5 CNGA3 GNAT2 GPR143 PAX6 RDX TUBB3
2 vision/eye MP:0005391 9.02 CNGA3 GNAT2 GPR143 PAX6 WDPCP

Drugs & Therapeutics for Pathologic Nystagmus

Drugs for Pathologic Nystagmus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 135)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gabapentin Approved, Investigational Phase 4,Phase 2,Not Applicable 60142-96-3 3446
2
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 2,Not Applicable 56-12-2 119
3
Memantine Approved, Investigational Phase 4,Phase 2,Not Applicable 19982-08-2 4054
4
Dopamine Approved Phase 4,Phase 2,Not Applicable 51-61-6, 62-31-7 681
5
Ketamine Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2 6740-88-1 3821
6
Morphine Approved, Investigational Phase 4 57-27-2 5288826
7
Haloperidol Approved Phase 4 52-86-8 3559
8
Brinzolamide Approved Phase 4 138890-62-7 68844
9
Ondansetron Approved Phase 4 99614-02-5 4595
10
Histamine Approved, Investigational Phase 4 75614-87-8, 51-45-6 774
11
Meclizine Approved Phase 4 569-65-3 4034
12 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 calcium channel blockers Phase 4,Phase 3,Phase 2,Not Applicable
14 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
15 GABA Agents Phase 4,Phase 2,Not Applicable
16 Serotonin Agents Phase 4,Not Applicable
17 Serotonin Antagonists Phase 4,Not Applicable
18 Gastrointestinal Agents Phase 4,Not Applicable
19 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Anesthetics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Tranquilizing Agents Phase 4,Phase 3,Phase 2,Not Applicable
22 Anti-Anxiety Agents Phase 4,Phase 3,Phase 2,Not Applicable
23 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Excitatory Amino Acids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Anticonvulsants Phase 4,Phase 3,Phase 2,Not Applicable
27 Antiemetics Phase 4,Not Applicable
28 Antiparkinson Agents Phase 4,Phase 2,Not Applicable
29 Psychotropic Drugs Phase 4,Phase 3,Phase 2,Not Applicable
30 Antimanic Agents Phase 4,Phase 2,Not Applicable
31 Autonomic Agents Phase 4,Not Applicable
32 Calcium, Dietary Phase 4,Phase 3,Phase 2,Not Applicable
33 decanoic acid Phase 4
34 Haloperidol decanoate Phase 4
35 Narcotics Phase 4
36 Gentamicins Phase 4,Not Applicable
37 Tetrahydrozoline Phase 4
38 Analgesics, Opioid Phase 4
39 Anesthetics, Dissociative Phase 4,Phase 3,Phase 1,Phase 2
40 Anesthetics, General Phase 4,Phase 3,Phase 1,Phase 2
41 Dermatologic Agents Phase 4,Early Phase 1
42 Anesthetics, Intravenous Phase 4,Phase 3,Phase 1,Phase 2
43 Ophthalmic Solutions Phase 4
44 Dopamine Agents Phase 4,Phase 2,Not Applicable
45 Dopamine Antagonists Phase 4
46 Anti-Bacterial Agents Phase 4,Not Applicable
47 Pharmaceutical Solutions Phase 4,Phase 2,Phase 1
48 Anti-Infective Agents Phase 4,Phase 1,Not Applicable
49 Antipruritics Phase 4
50 Antipsychotic Agents Phase 4

Interventional clinical trials:

(show top 50) (show all 79)
# Name Status NCT ID Phase Drugs
1 Treatment of Pendular Nystagmus in OPT Completed NCT02466191 Phase 4 Memantine;Gabapentin
2 Topical Brinzolamide Ophthalmic Suspension Versus Placebo in the Treatment of Infantile Nystagmus Syndrome Completed NCT01312402 Phase 4 topical brinzolamide 1% in 5mL ophthalmic medication;Placebo in 5 mL dispenser
3 Low-dose Ketamine vs Morphine for Vaso-occlusive Crisis in Sicklers Completed NCT02434939 Phase 4 Low dose ketamine;Morphine
4 Intravenous Haloperidol Versus Ondansetron for Treatment of Established Post-operative Nausea and Vomiting Completed NCT02143531 Phase 4 4 mg of Ondansetron IV;1mg of Haloperidol IV
5 Motion Sickness Medications and Vestibular Time Constant Recruiting NCT03270839 Phase 4 Bonine 25Mg Chewable Tablet;Kwells;Placebo Oral Tablet
6 Gentamicin Treatment Prior to Schwannoma Surgery - No Residual Function Recruiting NCT02415257 Phase 4 Gentamicin
7 Gentamicin Treatment Prior to Schwannoma Surgery - Residual Function Recruiting NCT02379754 Phase 4 Gentamicins
8 Treatment of Geotropic Horizontal Canal Benign Paroxysmal Positional Vertigo Completed NCT01366430 Phase 3
9 The Treatment of Posterior Semicircular Canal Benign Paroxysmal Positional Vertigo Completed NCT02029508 Phase 3
10 Treatment of Apogeotropic Horizontal Canal Benign Paroxysmal Positional Vertigo Completed NCT00810641 Phase 3
11 Efficacy of Ketamine Added to Local Anesthetic in Modified Pectoral Block for Management of Postoperative Pain Completed NCT02620371 Phase 3
12 Open-Label Extension Study Of Safety And Tolerability Of Pregabalin In Pediatric Patients With Partial-Onset Seizures Completed NCT00448916 Phase 3 Pregabalin
13 Bupivacaine Injection of Eye Muscles to Treat Strabismus Recruiting NCT01616108 Phase 2, Phase 3 Bupivacaine
14 Efficacy of SENS-111 in Patients Suffering From Acute Unilateral Vestibulopathy Recruiting NCT03110458 Phase 2, Phase 3 SENS-111 100mg;SENS-111 200mg;Placebo Oral Tablet
15 4-Aminopyridine in Episodic Ataxia Type 2 Unknown status NCT01543750 Phase 2 4-Aminopyridine;Placebo
16 Efficacy and Safety Study of Neramexane to Treat Congenital and Acquired Nystagmus Completed NCT00661440 Phase 2 Neramexane mesylate
17 Eye Muscle Surgery to Treat Congenital Nystagmus Completed NCT00001866 Phase 2
18 Treatment of Pendular Nystagmus With Gabapentin and Memantine in Patients With Multiple Sclerosis Completed NCT01744444 Phase 2 Memantine;Gabapentin
19 Treatment of Apogeotropic Horizontal Canal Benign Paroxysmal Positional Vertigo Completed NCT02046980 Phase 2
20 Prednisone Treatment for Vestibular Neuronitis Completed NCT00271791 Phase 2 Prednisone;Prednisone
21 Ketamine as Adjunctive Analgesic With Bupivacaine in Paravertebral Analgesia for Breast Cancer Surgery Completed NCT02462681 Phase 1, Phase 2 paravertebral block
22 Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures Recruiting NCT03355300 Phase 2 Cannabidiol Oral Solution
23 Repeated Dose IV Baclofen Safety/Bioequivalence Study Not yet recruiting NCT02760992 Phase 1, Phase 2 IV Baclofen;Oral Baclofen
24 Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus Terminated NCT00799942 Phase 2 Neramexane mesylate
25 Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) Terminated NCT01226745 Phase 2 ONO-4641;ONO-4641;ONO-4641;ONO-4641;ONO-4641;ONO-4641
26 A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS) Terminated NCT02855411 Phase 2 PF-04958242;placebo
27 A Study of 2-Iminobiotin in Neonates With Perinatal Asphyxia Terminated NCT01626924 Phase 2 2-Iminobiotin
28 Dose Escalation Study of Intravenous Baclofen in Healthy Adult Volunteers Completed NCT01931319 Phase 1 Intravenous baclofen
29 Oral and IV Baclofen in Adult Volunteers Completed NCT01749319 Phase 1 Oral baclofen;Intervenous baclofen
30 Multiple Ascending Doses of PF-04958242 in Subjects With Stable Schizophrenia Completed NCT02332798 Phase 1 PF-04958242;Placebo;PF-04958242;Placebo
31 Study To Evaluate The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-04958242 In Healthy Volunteers Completed NCT02228395 Phase 1 PF-04958242;Placebo
32 A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of PF-04958242 in Healthy Subjects Completed NCT02341482 Phase 1 PF-04958242;Itraconazole
33 A Blinded, Four-Way Crossover in Healthy Subjects to Assess EEG After Administration of Ketamine, Placebo and AZD6765 Terminated NCT01130909 Phase 1 AZD6765;AZD6765;Ketamine;Placebo
34 Treatment of Posterior Canal Type of Benign Paroxysmal Positional Vertigo Unknown status NCT01822002 Not Applicable
35 The Role of Corticosteroids and Vestibular Exercises in Recovery of Vestibular Neuritis Unknown status NCT01231009 Early Phase 1 Corticosteroids
36 The Effects of Gabapentin and Ramosetron on Postoperative Nausea and Vomiting in Laparoscopic Gynecological Surgery Unknown status NCT02617121 Not Applicable Gabapentin;Ramosetron;Gabapentin and Ramosetron
37 Cross-over Comparison of Gabapentin and Memantine as Treatment for Acquired Nystagmus Completed NCT00928954 Not Applicable gabapentin;memantine
38 Screening for Studies on Nystagmus and Strabismus Completed NCT00001861
39 Helpfulness of the Vibration Test Performed in Room Light on Clients With Inner Ear Problems Completed NCT02626052
40 BPPV Treatment in Biaxial Rotational Chair Completed NCT01905800 Not Applicable
41 Clinical Aspects of Patients With Benign Paroxysmal Positional Vertigo (BPPV) and Migraine Completed NCT02615314
42 Functional Link Between Hippocampal and Vestibular Systems: a Pilot Study in Epilepsy Surgery Completed NCT01285921 Not Applicable
43 Effect of Vestibular Rehabilitation - a Randomized Controlled Trial Completed NCT00702832 Not Applicable
44 Quantification of Prosthesis Penetration With Conebeam in Otosclerosis Completed NCT02901093
45 Vestibular Evoked Myogenic Potentials in Benign Paroxysmal Positional Vertigo (VEMP in BPPV) Completed NCT01004913
46 Vertigo Perception and Quality of Life in Patients After Surgical Treatment of Vestibular Schwannoma Completed NCT02963896 Not Applicable gentamicin
47 Early Versus Delayed Surgery for Infantile Esotropia Completed NCT01166503
48 Long-term Postoperative Outcomes After Bilateral Congenital Cataract Surgery in Eyes With Microphthalmos Completed NCT01818037
49 Telemedical Examination of a Three-Component Oculomotor Testing Battery Completed NCT02938221 Not Applicable
50 Correlation of Gene Abnormalities and Clinical Manifestations of Aniridia Completed NCT00265590

Search NIH Clinical Center for Pathologic Nystagmus

Genetic Tests for Pathologic Nystagmus

Anatomical Context for Pathologic Nystagmus

MalaCards organs/tissues related to Pathologic Nystagmus:

41
Eye, Testes, Brain

Publications for Pathologic Nystagmus

Articles related to Pathologic Nystagmus:

# Title Authors Year
1
Ethanol-induced resolution of pathologic nystagmus. ( 3619996 )
1987
2
A review of pathologic nystagmus. ( 615375 )
1977
3
Pathologic nystagmus: a classification based on electro-oculographic recordings. ( 1088538 )
1976

Variations for Pathologic Nystagmus

Expression for Pathologic Nystagmus

Search GEO for disease gene expression data for Pathologic Nystagmus.

Pathways for Pathologic Nystagmus

GO Terms for Pathologic Nystagmus

Cellular components related to Pathologic Nystagmus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuronal cell body GO:0043025 9.5 CNGA3 FRMD7 TUBB3
2 cytoskeleton GO:0005856 9.35 CCDC28B FRMD7 RDX TUBB3 WDPCP
3 apical plasma membrane GO:0016324 9.33 GPR143 RDX WDPCP
4 cell periphery GO:0071944 9.26 RDX TUBB3
5 photoreceptor outer segment membrane GO:0042622 8.62 CNGA3 GNAT2

Biological processes related to Pathologic Nystagmus according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 smoothened signaling pathway GO:0007224 9.32 PAX6 WDPCP
2 camera-type eye development GO:0043010 9.26 PAX6 WDPCP
3 establishment of protein localization GO:0045184 9.16 RDX WDPCP
4 regulation of ruffle assembly GO:1900027 8.96 RDX WDPCP
5 visual perception GO:0007601 8.92 CNGA3 GNAT2 GPR143 PAX6

Sources for Pathologic Nystagmus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....